Drug Search Results
More Filters [+]

Otamixaban

Alternative Names: otamixaban
Latest Update: 2023-06-27
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: FXa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Otamixaban

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Coronary Syndrome|Non-ST Elevated Myocardial Infarction|Angina, Stable|Angina, Unstable

Phase 2: Coronary Artery Disease|Acute Coronary Syndrome|Venous Thrombosis|Coronary Thrombosis|Coronary Disease

Phase 1: Other|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAO

P3

Completed

Acute Coronary Syndrome

2013-05-06

TAO

P3

Completed

Angina, Unstable|Angina, Stable|Acute Coronary Syndrome|Non-ST Elevated Myocardial Infarction

2013-05-01

POP6537

P1

Completed

Kidney Diseases

2011-07-01

POP6207

P1

Completed

Other

2011-04-01

Recent News Events